Primary Outcome Measures
Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 [Time Frame: Up to 8 weeks] [Designated as safety issue: ]
Time to Cmax (Tmax) of ABBV-927 [Time Frame: Up to 12 weeks after participant's first dose] [Designated as safety issue: ]
Maximum observed serum concentration (Cmax) of ABBV-927 [Time Frame: Up to 12 weeks after participant's first dose] [Designated as safety issue: ]
Terminal-Phase Elimination Rate Constant (ß) of ABBV-927 [Time Frame: Up to 12 weeks after participant's first dose] [Designated as safety issue: ]
Terminal half-life (t1/2) of ABBV-927 [Time Frame: Up to 4 weeks after participant's first dose] [Designated as safety issue: ]
Area under the serum concentration-time curve (AUCt) of ABBV-927 [Time Frame: Up to 12 weeks after participant's first dose] [Designated as safety issue: ]
Time to Cmax (Tmax) of ABBV-181 [Time Frame: Up to 12 weeks after participant's first dose] [Designated as safety issue: ]
Maximum observed serum concentration (Cmax) of ABBV-181 [Time Frame: Up to 12 weeks after participant's first dose] [Designated as safety issue: ]
Terminal-Phase Elimination Rate Constant (ß) of ABBV-181 [Time Frame: Up to 12 weeks after participant's first dose] [Designated as safety issue: ]
Terminal half-life (t1/2) of ABBV-181 [Time Frame: Up to 4 weeks after participant's first dose] [Designated as safety issue: ]
Area under the serum concentration-time curve (AUCt) of ABBV-181 [Time Frame: Up to 12 weeks after participant's first dose] [Designated as safety issue: ]
Number of Participants with Adverse Events [Time Frame: Up to 30 days after and up to 24-month of treatment period] [Designated as safety issue: ]
Secondary Outcome Measures
Clinical benefit rate (CBR, defined as the percentage of participants with a confirmed partial, complete response, or stable disease for at least 24 weeks to the treatment) [Time Frame: Up to 30 days after and up to 24-month of treatment period] [Designated as safety issue: ]
Duration of objective response (DOR) [Time Frame: Up to 30 days after and up to 24-month of treatment period] [Designated as safety issue: ]
Objective response rate (ORR) [Time Frame: Up to 30 days after and up to 24-month of treatment period] [Designated as safety issue: ]
Progression-free survival (PFS) [Time Frame: Up to 30 days after and up to 24-month of treatment period] [Designated as safety issue: ]